Scinai Immunotherapeutics
(NASDAQ) SCNI
Scinai Immunotherapeutics Financials at a Glance
Market Cap
$2.01M
Revenue (TTM)
$1.31M
Net Income (TTM)
$8.82M
EPS (TTM)
$-12.27
P/E Ratio
-0.05
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Price
$0.58
Volume
28,673
Open
$0.60
Price
$0.58
Volume
28,673
Open
$0.60
Previous Close
$0.58
Daily Range
$0.57 - $0.61
52-Week Range
$0.55 - $6.18
Dividend
$0.00
Beta (Volatility)
0.96 (Low)
Price
$0.58
Volume
28,673
Open
$0.60
Previous Close
$0.58
Daily Range
$0.57 - $0.61
52-Week Range
$0.55 - $6.18
SCNI News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Scinai Immunotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
31
CEO
Amir Reichman, MBA
Website
www.scinai.comHeadquarters
Jerusalem, IL
SCNI Financials
Key Financial Metrics (TTM)
Gross Margin
-2%
Operating Margin
-6%
Net Income Margin
-7%
Return on Equity
0%
Return on Capital
-75%
Return on Assets
-76%
Earnings Yield
-20.00%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.01M
Shares Outstanding
3.47M
Volume
28.67K
Short Interest
0.00%
Avg. Volume
55.10K
Financials (TTM)
Gross Profit
$2.65M
Operating Income
$7.54M
EBITDA
$6.53M
Operating Cash Flow
$6.03M
Capital Expenditure
$24.00K
Free Cash Flow
$6.05M
Cash & ST Invst.
$1.66M
Total Debt
$2.27M
Scinai Immunotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$260.71K
+26.6%
Gross Profit
$1.38M
-727.5%
Gross Margin
-5.30%
N/A
Market Cap
$2.01M
N/A
Market Cap/Employee
$64.97K
N/A
Employees
31
N/A
Net Income
$2.57M
-15.3%
EBITDA
$3.19M
-91.5%
Quarterly Fundamentals
Net Cash
$606.00K
-210.8%
Accounts Receivable
$168.00K
+40.0%
Inventory
$0.00
N/A
Long Term Debt
$1.94M
+124.6%
Short Term Debt
$329.00K
-9.6%
Return on Assets
-75.91%
N/A
Return on Invested Capital
-75.11%
N/A
Free Cash Flow
$1.29M
+26.7%
Operating Cash Flow
$1.29M
+26.8%